In the United States, pancreatic adenocarcinoma is the fourth leading cause of adult cancer mortality. Ten percent of cases of pancreatic cancer are hereditary. With earlier detection, the prognosis could, theoretically, be improved. Researchers are studying families with an increased incidence of pancreatic cancer to identify a population at high risk for pancreatic adenocarcinoma. Endosonography or endoscopic ultrasound (EUS) is useful in imaging the pancreas, making early detection a possibility. EUS screening in patients with a history of this disease may help identify a precursor lesion to pancreatic cancer.
In the United States, pancreatic adenocarcinoma is the fourth leading cause of adult cancer mortality. In an estimated 10% of cases, this disease is hereditary. Methods to evaluate patients with suspected pancreatic adenocarcinoma currently include endoscopic retrograde cholangiopancreatography (ERCP), abdominal computed tomography (CT), transabdominal ultrasound, and serum tumor markers. 1 Using these methods, it is difficult to detect pancreatic cancer until it is in an advanced stage. At this time, the 1-year survival rate for pancreatic cancer is exceedingly poor. With earlier detection, the prognosis could, theoretically, be improved. 1 Early detection may be possible if endoscopic ultrasound (EUS) is used to screen patients at high risk for inheriting pancreatic cancer.
Familial Links
Because it is difficult to identify pancreatic cancer in an early stage, it has not been possible to identify early molecular changes that are associated with development of pancreatic malignancy. 2 Researchers are studying families with an increased incidence of pancreatic cancer to identify a population at high risk for pancreatic adenocarcinoma. In a study by Brentnall et al., 1 families qualified as high risk if 2 or more mem-bers in 2 generations were diagnosed with pancreatic cancer. Atypical ductal hyperplasia, also referred to as pancreatic dysplasia, is believed to be the precursor lesion to pancreatic cancer. 1 Therefore, it would be best to make a diagnosis of dysplasia before cancer has developed. Studies have indicated that the age of onset, sex ratio, pathology, and prognosis are strikingly similar to pancreatic cancer as manifested in the general population. Researchers hope that once they are able to identify these patients with hereditary pancreatic cancer, they will be able to use this information to identify other patients with the disease in its early stages.
A pattern of pancreatic cancer suggestive of an autosomal dominantly inherited factor has been shown in studies of extended families. 3 Once inheritance factors are extended and hereditary cancer syndrome diagnoses are secure, the potential for cancer control may be enormous. 3 In the families that have been studied, many pathologic conditions have been sited as increasing the patient's risk for developing pancreatic cancer. Lynch et al. 3 believe that a thoroughly constructed pedigree that exposes excess pancreatic cancer in a pattern consistent with a hereditary syndrome would be the basis for genetic screening. Brentnall et al. 1 used pancreatic endocrine and exocrine insufficiency as a clinical marker for a family whose members are at greatest risk for pancreatic cancer. It has been shown that clinically evident pancreatitis increases the subsequent risk for pancreatic carcinoma. 2 In a study of 21 families whose members had pancreatitis, the prevalence of pancreatic cancer was 20%. Researchers have shown compelling evidence that patients with long-standing diabetes have an increased frequency of pancreatic cancer. Site-specific pancreatic cancer has also been described as occurring in families. 3 Also noted in some families is the development of pancreatic cancer at a young age.
EUS: A Screening Test
Endosonography or EUS is useful in imaging the pancreas. An endoscope with a high-frequency (7 to 12 MHz) transducer is placed in the patient's stomach or duodenum to visualize the pancreas (Figs. 1, 2 ). Acoustic contact is by water filling the gastrointestinal tract lumen or water filling a small balloon over the transducer. 3 EUS requires the combined expertise of an endoscopist and a sonologist. 4 In cases of pancreatic cancer, EUS is preferred over CT or transabdominal ultrasound. The preference for endoscopic ultrasound over transabdominal ultrasound is due to its ability to produce a more detailed image by using a higher frequency transducer. EUS also demonstrates the pancreas better because placing the transducer in the stomach or duodenum eliminates overlying bowel gas. Because of these advantages, EUS is especially useful in detecting pancreatic lesions that are smaller than 3 cm. The EUS detection rate for these lesions is near 100%, whereas transabdominal ultrasound detects only 50%. 4 Histologic examination revealed that dysplasia first occurred in the small to medium-sized ducts in study patients. 1 Using the detailed imaging of EUS, these changes in the small to medium-sized ducts could be better evaluated.
In the study by Brentnall et al., 1 EUS was performed in 14 patients. Ten of these patients had findings that ranged from mild to moderately abnormal. The common findings during endosonography included heterogeneous parenchyma with 1 to 2 mm of scattered foci, hypoechoic nodules 2 to 4 mm in diameter, hyperechoic main ducts, and discrete masses. Three of the 14 patients in the study were asymptomatic and had normal results on EUS. One patient's results were not available for review. Six of the 7 patients with abnormal EUS findings had abnormal findings on ERCP as well. All 6 were found to have widespread ductal dysplasia at pancreatectomy. 5 None of the patients had invasive cancer.
EUS is an excellent screening tool because it does not cause pancreatitis as ERCP does and has a complication rate of less than 1%. EUS screening in patients with a history of this disease may identify a precursor lesion to pancreatic cancer. 5 EUS is also better at characterizing a mass in the pancreas with regard to tumor margin, shape, echogenicity, and echotexture. The sensitivity of this screening has been reported to be as high as 98% to 100%. 4 The role of EUS is still changing. Currently, researchers believe it is reasonable to begin testing high-risk patients in early adulthood. One study stated that screenings should begin at an age 5 years younger than the age of earliest onset within the family. High-frequency mini probes that could be useful in the search for an intraductal lesion are being developed. 4 A current limitation of EUS is that it is not possible to differentiate focal pancreatitis from cancer. Use of needle biopsy during EUS has been found to be safe in initial studies and should provide greater accuracy in the differential diagnosis of pancreatic abnormalities.
Case Study
Two members of 1 family are participating in a study for hereditary pancreatic carcinoma in which they are followed up once per year using EUS. They are being studied because their mother died of pancreatic adenocarcinoma at age 54. At this time, 1 patient (I), a 31-year-old man, had a normal-appearing pancreas by EUS ( Fig. 3 ). His brother (II), a 28-year-old man, had abnormal results on his scan. The pancreas was mildly heterogeneous, with multiple 1 to 2 mm hyperechoic foci and mildly hyperechoic main duct walls (Fig. 4) . No peripancreatic adenopathy was identified. At a 6-month follow-up study, the patient had an ERCP and a CT scan, which both showed a normal pancreas. Repeat EUS demonstrated a mild increase in echogenicity of his pancreatic ducts. He will continue to be followed up at 6-month intervals. 
Conclusion
In an attempt to improve the prognosis of patients with pancreatic adenocarcinoma, research is being conducted to identify high-risk patients. Several studies have found consistent changes in families where pancreatic cancer is inherited. EUS can be used as a highly accurate, noninvasive screening tool in these high-risk patients. EUS has excellent resolution when scanning the pancreas; therefore, small changes that may not be apparent on other imaging studies can be seen on EUS. These findings are extremely valuable in detecting dysplasia of the pancreas, which is believed to be the precursor lesion to pancreatic cancer. Continued research and new developments in EUS will improve its diagnostic capabilities and aid in an improved prognosis for patients at high risk of developing pancreatic adenocarcinoma. 
